Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Jun;4(6):818–828. doi: 10.1158/1940-6207.CAPR-10-0376

Figure 3.

Figure 3

Kaplan-Meier survival estimates and effects of hypertriglyceridemia or rash on survival in the phase II bexarotene and erlotinib lung cancer trial. (A) Overall survival. (B) Improved survival after appearance of hypertriglyceridemia (P = 0.001) or (C) rash (P = 0.03).